
News|Articles|September 29, 2023
The Durability of Roctavian and the Need for Corticosteroids
Author(s)Peter Wehrwein, Managing Editor
Data from clinical trials suggest that the vast majority of the patients respond to the gene therapy for hemophilia A, says Courtney Thornburg, M.D., M.S. But there is also decreasing factor expression.
Advertisement
Second of four parts
In this segment of a video interview with Managed Healthcare Executive, Courtney Thornburg, M.D., M.S., discusses the durability of Roctavian (valoctocogene roxaparvovec) in producing factor VIII and liver inflammation that is treated with corticosteroids.
Thornburg, the medical director of the Hemophilia and Thrombosis Treatment Center at Rady Children’s Hospital-San Diego, was the lead author of a review article about hemophilia gene therapy that was published in July in the journal BioDrugs.
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Retatrutide shows substantial weight loss, glycemic control in obesity and type 2 diabetes | ADA 2026
2
Pivotal trial is recruiting for monthly GLP-1 for weight loss | ADA 2026
3
CONNECT data support CGM use in non-insulin type 2 diabetes management | ADA 2026
4
‘Fierce compassion’ could be key to minimizing shame in HIV patients
5































